Innoviva (INVA) Equity Ratio (2010 - 2026)
Innoviva posted quarterly Equity Ratio of 0.73 for Q1 2026, up 41.65% year-on-year from 0.52 in Q1 2025, and up 1.85% on a QoQ basis from 0.72 in Q4 2025.
Innoviva (INVA) has 17 years of Equity Ratio data on file, last reported at 0.73 in Q1 2026.
- For the quarter ending Q1 2026, Equity Ratio rose 41.65% year-over-year to 0.73; the trailing twelve-month figure through Mar 2026 stood at 0.73 (up 41.65% YoY), and the FY2025 full-year result was 0.72, up 35.02% from the prior year.
- Equity Ratio for Q1 2026 stood at 0.73, up from 0.72 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.73 in Q1 2026 and bottomed at 0.46 in Q4 2022.
- The 5-year median for Equity Ratio is 0.53 (2024), against an average of 0.55.
- The widest annual swing landed in 2022, when Equity Ratio fell 22.11%; it then jumped 41.65% in 2026.
- A 5-year view of Equity Ratio shows it stood at 0.46 in 2022, then gained by 18.14% to 0.54 in 2023, then fell by 2.13% to 0.53 in 2024, then soared by 35.02% to 0.72 in 2025, then rose by 1.85% to 0.73 in 2026.
- The last three Equity Ratio figures came in at 0.73 (Q1 2026), 0.72 (Q4 2025), and 0.71 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.73 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.77 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.21 |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 0.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.73 |
| Dec 31, 2025 | 0.72 |
| Sep 30, 2025 | 0.71 |
| Jun 30, 2025 | 0.54 |
| Mar 31, 2025 | 0.52 |
| Dec 31, 2024 | 0.53 |
| Sep 30, 2024 | 0.54 |
| Jun 30, 2024 | 0.54 |
| Mar 31, 2024 | 0.56 |
| Dec 31, 2023 | 0.54 |
| Sep 30, 2023 | 0.53 |
| Jun 30, 2023 | 0.50 |
| Mar 31, 2023 | 0.50 |
| Dec 31, 2022 | 0.46 |
| Sep 30, 2022 | 0.48 |
| Jun 30, 2022 | 0.50 |
| Mar 31, 2022 | 0.50 |
| Dec 31, 2021 | 0.57 |
| Sep 30, 2021 | 0.55 |
| Jun 30, 2021 | 0.50 |
| Mar 31, 2021 | 0.64 |
| Dec 31, 2020 | 0.61 |
| Sep 30, 2020 | 0.58 |
| Jun 30, 2020 | 0.56 |
| Mar 31, 2020 | 0.52 |
| Dec 31, 2019 | 0.47 |
| Sep 30, 2019 | 0.42 |
| Jun 30, 2019 | 0.38 |
| Mar 31, 2019 | 0.34 |
| Dec 31, 2018 | 0.29 |
| Sep 30, 2018 | -0.39 |
| Jun 30, 2018 | -0.46 |
| Mar 31, 2018 | -0.77 |
| Dec 31, 2017 | -0.66 |
| Sep 30, 2017 | -0.57 |
| Jun 30, 2017 | -0.80 |
| Mar 31, 2017 | -0.85 |
| Dec 31, 2016 | -0.93 |
| Sep 30, 2016 | -0.99 |
| Jun 30, 2016 | -0.96 |
| Mar 31, 2016 | -0.93 |
| Dec 31, 2015 | -0.84 |
| Sep 30, 2015 | -0.74 |
| Jun 30, 2015 | -0.64 |
| Mar 31, 2015 | -0.53 |
| Dec 31, 2014 | -0.43 |
| Sep 30, 2014 | -0.35 |
| Jun 30, 2014 | -0.31 |
| Mar 31, 2014 | 0.44 |
| Dec 31, 2013 | 0.44 |
| Sep 30, 2013 | 0.50 |
| Jun 30, 2013 | 0.14 |
| Mar 31, 2013 | 0.15 |
| Dec 31, 2012 | 0.42 |
| Sep 30, 2012 | 0.45 |
| Jun 30, 2012 | 0.47 |
| Mar 31, 2012 | 0.03 |
| Dec 31, 2011 | -0.34 |
| Sep 30, 2011 | -0.21 |
| Jun 30, 2011 | -0.12 |
| Dec 31, 2010 | -0.07 |